Mark Stejbach
Director/Board Member bij INDIVIOR PLC
Vermogen: 271 431 $ op 31-03-2024
Profiel
Mark P.
Stejbach is an Independent Non-Executive Director at Indivior PLC since 2021.
He was previously an Independent Director at Flexion Therapeutics, Inc. from 2016 to 2021, a Director at Commonwealth National Fund, Inc. from 2003 to 2011, a Principal at Biogen MA, Inc. in 1997, and a Vice President-Managed Care Marketing at Merck & Co., Inc. from 1987 to 2008.
He also served as the Chief Commercial Officer & Head-Media Relations at Tengion, Inc. in 2011 and as the Chief Commercial Officer & Senior Vice President at Alkermes Plc from 2012 to 2018.
Stejbach received his undergraduate degree from Virginia Polytechnic Institute & State University and his MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INDIVIOR PLC
0.01% | 01-03-2024 | 12 684 ( 0.01% ) | 271 431 $ | 31-03-2024 |
Actieve functies van Mark Stejbach
| Bedrijven | Functie | Begin |
|---|---|---|
| INDIVIOR PLC | Director/Board Member | 24-03-2021 |
Eerdere bekende functies van Mark Stejbach
| Bedrijven | Functie | Einde |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19-11-2021 |
| ALKERMES PLC | Corporate Officer/Principal | 01-10-2018 |
| TENGION, INC. | Public Communications Contact | 01-01-2012 |
Commonwealth National Fund, Inc.
 Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Director/Board Member | 01-01-2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01-07-2008 |
Opleiding van Mark Stejbach
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| TENGION, INC. | Health Technology |
| INDIVIOR PLC | Health Technology |
| ALKERMES PLC | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Finance |
